A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Status:
RECRUITING

Trial end date:
2028-07-05

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose of ALN-HTT02.

PHASE1

Alnylam Pharmaceuticals